Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01920061 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT01920061 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 110 participants.
The verdict
NCT01920061, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in order to determine the maximum tolerated dose in each combination. The cisplatin combination expansion portion will evaluate the anti tumor activity of PF 05212384 plus cisplatin in patients with TNBC in 2 separate Arms (Arm 1 and Arm 2).
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Dacomitinib
- DRUG PF-05212384 (gedatolisib)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2013-09-10 |
| Est. Completion | 2020-01-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01920061
The ClinicalTrials.gov registry entry for NCT01920061 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01920061 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01920061 about?
NCT01920061 is a clinical study titled "A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)". This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors. The study will assess the safety, pharmacokinetics and pharmacodynamics of these combinations in patients with advanced cancer in o...
What is the current status of trial NCT01920061?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2013-09-10. Estimated completion is 2020-01-08.
What interventions are being tested in trial NCT01920061?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Dacomitinib (DRUG), PF-05212384 (gedatolisib) (DRUG).
Who is sponsoring clinical trial NCT01920061?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.